Abbvie-Header Abbvie-Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Vidofludimus calcium anhydrous

            Therapeutic Area: Immunology Product Name: IMU-838

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Immunic Therapeutics

            Deal Size: $17.2 million Upfront Cash: Undisclosed

            Deal Type: Agreement March 31, 2021

            Details:

            The acquisition of the royalties will enable Immunic to realize the full market potential of IMU-838, not only as a treatment for RRMS but also as a potential new therapeutic option for ulcerative colitis, Crohn’s disease, COVID-19, and primary sclerosing cholangitis.